$BYSI News

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Q2 EPS $(0.02) Up From $(0.04) YoY

BeyondSpring's Subsidiary SEED Therapeutics Has Received FDA Orphan Drug Designation For ST-01156 For Treatment Of Neuroblastoma

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

BeyondSpring Appoints Min Qiu As CEO, Effective July 1

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

Beyondspring Announces Updated Efficacy And Safety Data From Its Phase 2 303 Study Evaluating Pembrolizumab Plus Plinabulin And Docetaxel In Patients With Metastatic Non-Small Cell Lung Cancer; Sees Meaningful Clinical Benefit

BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Q1 EPS $(0.05) Up From $(0.06) YoY

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

BeyondSpring Files 2025 Annual Report on Form 10-K

BeyondSpring Reports 2025 Year-End Financial Results

BeyondSpring Q4 EPS $(0.05)

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

BeyondSpring Announces Asian Subset Results From Phase 3 DUBLIN-3 Trial Of Plinabulin In EGFR Wild-Type NSCLC At ESMO Asia 2025

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025